AbCellera Biologics (ABCL) Other Non Operating Income (2020 - 2026)

AbCellera Biologics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• Quarterly Other Non Operating Income rose 4.48% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (up 89.47% YoY) and the FY2025 annual result came in at -$2.7 million, down 119.9% from the prior year.
• Other Non Operating Income was $4.3 million for Q1 2026 at AbCellera Biologics, up from -$13.3 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $10.8 million in Q4 2022 and bottomed at -$34.9 million in Q4 2024.
• A 5-year average of $403176.5 and a median of $3.4 million in 2023 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 418.0% — and 2024, when it tumbled 1135.07%.
• AbCellera Biologics' Other Non Operating Income stood at $10.8 million in 2022, then sank by 68.8% to $3.4 million in 2023, then tumbled by 1135.07% to -$34.9 million in 2024, then soared by 61.98% to -$13.3 million in 2025, then soared by 132.66% to $4.3 million in 2026.
• Business Quant data shows ABCL's Other Non Operating Income at $4.3 million in Q1 2026, -$13.3 million in Q4 2025, and $2.7 million in Q3 2025.